Pursuant to Regulation 30 of Listing Regulations, Wockhardt has informed that it enclosed a Press Release titled ‘Wockhardt files fast-acting Insulin Aspart injection (ASPARAPIDTM) with DCGI; strengthens commitment to diabetes management’. A copy of the same will also be uploaded on the Company’s website www.wockhardt.com.
The above information is a part of company’s filings submitted to BSE.